IMTX.US Immatics NV

Healthcare Biotechnology USA Stocks
6.39 USD
Close of Nov 15, 2026
6.09 12.41
Market cap
USD 973M
P/E
-
P/B
2.00x
ROE
-59.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is IMTX.US undervalued?

Graham number

The Graham number of Immatics NV cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Immatics NV fundamental analysis

No fundamental analysis for Immatics NV yet.

Immatics NV stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Immatics NV

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME c…

Full company profile